Aldeyra Therapeutics, Inc. (ALDX)
USD 4.88
(-8.44%)
USD 4.88
(-8.44%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -30.32 Million | -56.63 Million | -42.55 Million | -37.49 Million | -44.98 Million | -29.85 Million |
| Net Income | -37.54 Million | -62.02 Million | -57.77 Million | -37.55 Million | -60.82 Million | -38.89 Million |
| Depreciation & Amortization | 262.78 Thousand | 258.7 Thousand | 264.18 Thousand | 56.22 Thousand | 96.3 Thousand | 71 Thousand |
| Deferred income taxes | -1.2 Million | - | - | -479.26 Thousand | -1.3 Million | -237.54 Thousand |
| Stock-based compensation | 5.75 Million | 8.28 Million | 7.1 Million | 7.08 Million | 8.08 Million | 4.14 Million |
| Change in working capital | 861.18 Thousand | -3.44 Million | 7.43 Million | -8.82 Million | 2.74 Million | 4.99 Million |
| Other non-cash items | 1.54 Million | 283.9 Thousand | 409.47 Thousand | 2.22 Million | 6.23 Million | 59.32 Thousand |
| Investing Cash Flow | 30 Million | -29.95 Million | -7806.00 | 29.02 Million | 18.47 Million | -23.33 Million |
| Investments in PPE | -2.00 | -16.31 Thousand | -7806.00 | - | -9529.00 | -262.96 Thousand |
| Acquisitions | - | 16.31 Thousand | - | - | 609.46 Thousand | 262.96 Billion |
| Investment purchases | - | -92.93 Million | - | -5.77 Million | -57.76 Million | -59.73 Million |
| Sales/Maturities of investments | 30 Million | 63 Million | - | 34.8 Million | 75.64 Million | 36.65 Million |
| Other Investing Activities | 30 Thousand | -16.31 Thousand | -7.8 Billion | 29.02 Thousand | 18.48 Thousand | -262.96 Billion |
| Financing Cash Flow | -1.27 Million | 1.22 Million | 194.49 Million | 41.9 Million | 23.57 Million | 80.52 Million |
| Debt repayment | -1.04 Million | - | - | - | -14.32 Million | -1.39 Million |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | -532.95 Thousand | - | - | - | - | - |
| Common Stock Issuance | 305.23 Thousand | 1.12 Million | 189.81 Million | 41.9 Million | 7.89 Million | 81.92 Million |
| Other Financing Activities | -532.95 Thousand | 96.66 Thousand | 4.68 Million | 41.9 Million | 30.01 Million | -1.39 Million |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | 1.2 Million | -886.07 Thousand | 638.06 Thousand | -426.66 Thousand | -2.84 Million | 2.04 Million |
| Inventory | - | - | - | - | - | - |
| Other working capital | -343.25 Thousand | -2.55 Million | 6.8 Million | -8.4 Million | 5.58 Million | 2.94 Million |
| Cash at beginning of period | 144.41 Million | 229.79 Million | 77.85 Million | 44.42 Million | 47.35 Million | 20.02 Million |
| Cash at end of period | 142.82 Million | 144.41 Million | 229.79 Million | 77.85 Million | 44.42 Million | 47.35 Million |
| Capital Expenditure | -2.00 | -16.31 Thousand | -7806.00 | - | -9529.00 | -262.96 Thousand |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | -1.59 Million | -85.37 Million | 151.93 Million | 33.43 Million | -2.93 Million | 27.33 Million |
| Free Cash Flow | -30.32 Million | -56.65 Million | -42.56 Million | -37.49 Million | -44.99 Million | -30.12 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -16.84 Million | -8.08 Million | -37.54 Million | -4.75 Million | -8.18 Million | -8.98 Million |
| Depreciation & Amortization | 61.63 Thousand | 60.63 Thousand | 262.78 Thousand | 66.46 Thousand | 64.99 Thousand | 64.34 Thousand |
| Deferred income taxes | - | - | -1.2 Million | 1.75 Million | - | - |
| Stock-based compensation | 1.93 Million | 1.54 Million | 5.75 Million | -800.34 Thousand | 789.21 Thousand | 1.57 Million |
| Change in working capital | 2.11 Million | -3.38 Million | 861.18 Thousand | 5.91 Million | -788.2 Thousand | -6.1 Million |
| Other non-cash items | 1.59 Million | 2.61 Million | 1.54 Million | -1.68 Million | 95.94 Thousand | 100.34 Thousand |
| Investing Cash Flow | -18.23 Million | -30.37 Million | 30 Million | - | - | - |
| Investments in PPE | -2.00 | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | -30.23 Million | -30.37 Million | - | - | - | - |
| Sales/Maturities of investments | 12 Million | - | 30 Million | - | - | - |
| Other Investing Activities | -18.23 Million | -30.37 Thousand | 30 Thousand | - | - | - |
| Financing Cash Flow | - | 18.19 Thousand | -1.27 Million | -1.01 Million | -315.75 Thousand | 5292.00 |
| Debt repayment | - | - | -1.04 Million | -1.04 Million | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | -532.95 Thousand | 532.95 | -532.95 Thousand | - |
| Common Stock Issuance | - | 18.19 Thousand | 305.23 Thousand | 30.18 Thousand | 217.19 Thousand | 5292.00 |
| Other Financing Activities | - | 18.19 | -532.95 Thousand | -1.04 Million | -532.95 Thousand | 5292.00 |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | -25.86 Thousand | -1.05 Million | 1.2 Million | 1.09 Million | -23.62 Thousand | -158.86 Thousand |
| Inventory | - | - | - | - | - | - |
| Other working capital | 2.13 Million | -2.32 Million | -343.25 Thousand | 4.82 Million | -764.57 Thousand | -5.95 Million |
| Cash at beginning of period | 52.49 Million | 142.82 Million | 144.41 Million | 143.33 Million | 151.67 Million | 165.02 Million |
| Cash at end of period | 31.02 Million | 52.49 Million | 142.82 Million | 142.82 Million | 143.33 Million | 151.67 Million |
| Capital Expenditure | -2.00 | - | - | - | - | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | -21.46 Million | -90.33 Million | -1.59 Million | -511.87 Thousand | -8.34 Million | -13.35 Million |
| Free Cash Flow | -13.22 Million | -9.97 Million | -30.32 Million | 500.44 Thousand | -8.02 Million | -13.35 Million |
BYAGF
OTLC
CLX
8254
VSOGF
3823